Last week ProMetic announced that it had closed patient enrolment in its phase II open label study in patients suffering from type II diabetes and metabolic syndrome and will transition to a pivotal placebo-controlled phase II study in patients suffering from type II diabetes.
10 Dec 2015
Statistically significant improvement in blood glucose control shown in Type II diabetes trial
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Statistically significant improvement in blood glucose control shown in Type II diabetes trial
ProMetic Life Sciences (PLI:TSE) | 0 0 1.3% | Mkt Cap: 1,075m
- Published:
10 Dec 2015 -
Author:
Derren Nathan -
Pages:
9
Last week ProMetic announced that it had closed patient enrolment in its phase II open label study in patients suffering from type II diabetes and metabolic syndrome and will transition to a pivotal placebo-controlled phase II study in patients suffering from type II diabetes.